Alzheimer's disease as type 3 diabetes: common pathophysiological mechanisms between Alzheimer's disease and type 2 diabetes
Open accessThe DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Abstract
Globally, the incidence of type 2 diabetes mellitus (T2DM) and Alzheimer’s disease (AD) epidemics is increasing rapidly and has huge financial and emotional costs. The purpose of the current review article is to discuss the shared pathophysiological connections between AD and T2DM. Research findings are presented to underline the vital role that insulin plays in the brain’s neurotransmitters, homeostasis of energy, as well as memory capacity. The findings of this review indicate the existence of a mechanistic interplay between AD pathogenesis with T2DM and, especially, disrupted insulin signaling. AD and T2DM are interlinked with insulin resistance, neuroinflammation, oxidative stress, advanced glycosylation end products (AGEs), mitochondrial dysfunction and metabolic syndrome. Beta-amyloid, tau protein and amylin can accumulate in T2DM and AD brains. Given that the T2DM patients are not routinely evaluated in terms of their cognitive status, they are rarely treated for cognitive impairment. Similarly, AD patients are not routinely evaluated for high levels of insulin or for T2DM. Studies suggesting AD as a metabolic disease caused by insulin resistance in the brain also offer strong support for the hypothesis that AD is a type 3 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Free radicals and antioxidants in normal physiological functions and human disease
Valko, M., Leibfritz, D., Moncol, J., Cronin, M. T. D., Mazur, M., & Telser, J. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2006.07.001 · Cited by 14,269 · cited 2×
“It leads to oxidation of proteins, lipids and DNA, causing damage to the mitochondria, as well as induction of genetic mutations in DNA/RNA [91]).”
BackgroundSaeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A. A., Ogurtsova, K., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107843 · Cited by 10,792 · cited 1×
“It is estimated that the global diabetes mellitus (DM) prevalence will rise from 9.3% (463 million people) in 2019 to 10.2% (578 million) by 2030 and 10.9% (700 million) by 2045 [8].”
BackgroundInfluentialHearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459 · cited 1×
“The strongest genetic risk factor for AD is the e4 allele of apolipoprotein E (APOE4) relative to the e3 allele and the protective e2 allele [5,6].”
BackgroundType 2 diabetes: principles of pathogenesis and therapy
Stumvoll, M., Goldstein, B. J., & van Haeften, T. W. (2005) · The Lancet · doi:10.1016/s0140-6736(05)61032-x · Cited by 2,662 · cited 2×
“This dysfunction means that the secretion of insulin by the β-cells of the pancreatic islets (β-cell dysfunction) as well as the action of insulin on insulin-sensitive tissues such as the liver, adipose tissue and muscle do not function normally for the body (insulin resistance) [9].”
BackgroundProtein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade
Chiti, F., & Dobson, C. M. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-045115 · Cited by 2,629 · cited 1×
“AD and T2DM are both diseases that involve the formation of amyloid in various parts of the body [42,43].”
BackgroundAdvanced Glycation End Products: Sparking the Development of Diabetic Vascular Injury
Goldin, A., Beckman, J. A., Schmidt, A. M., & Creager, M. A. (2006) · Circulation · doi:10.1161/circulationaha.106.621854 · Cited by 2,261 · cited 1×
“These products are protein molecules or peptides that are formed as a result of the Maillard reaction, meaning they become glycated as a result of their exposure to sugars [105].”
BackgroundTau in physiology and pathology
Wang, Y., & Mandelkow, E. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.1 · Cited by 2,251 · cited 1×
“In its normal state, tau protein is responsible for microtubule stability and regulating intracellular signaling [63–66].”
Background2021 Alzheimer's disease facts and figures
(2021) · Alzheimer's & Dementia · doi:10.1002/alz.12328 · Cited by 2,201
Diabetes mellitus and the risk of dementia: The Rotterdam Study
Ott, A., Stolk, R. P., van Harskamp, F., Pols, H. A. P., Hofman, A., & Breteler, M. M. B. (1999) · Neurology · doi:10.1212/wnl.53.9.1937 · Cited by 2,175 · cited 1×
“Insulin resistance affects the way insulin works in target tissues and cells, leading to the well-known phenomenon of hyperglycemia, a condition in which too much glucose circulates in the blood plasma and characterizes T2DM [9] T2DM has also been associated with an increased risk of dementia [10,11] and of AD by 45–9…”
BackgroundTalbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871 · cited 1×
“These metabolic disorders, which accompany AD even from its early stages [26,127], lead to exacerbations of insulin signaling disorders, glucose use and insulin resistance problems [20,34,128], such as decreased acetylcholine (ACh) levels [20], with further aggravation of the pathological condition for those carrying…”
BackgroundSteen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703 · cited 1×
“These metabolic disorders, which accompany AD even from its early stages [26,127], lead to exacerbations of insulin signaling disorders, glucose use and insulin resistance problems [20,34,128], such as decreased acetylcholine (ACh) levels [20], with further aggravation of the pathological condition for those carrying…”
BackgroundFree radicals, reactive oxygen species, oxidative stress and its classification
Lushchak, V. I. (2014) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2014.10.016 · Cited by 1,649 · cited 1×
“Reactive forms of oxygen enhance cell apoptosis and promote the production of inflammatory cytokines [91,92].”
BackgroundCognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications
Biessels, G. J., & Despa, F. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0048-7 · Cited by 1,454 · cited 1×
“Insulin resistance affects the way insulin works in target tissues and cells, leading to the well-known phenomenon of hyperglycemia, a condition in which too much glucose circulates in the blood plasma and characterizes T2DM [9] T2DM has also been associated with an increased risk of dementia [10,11] and of AD by 45–9…”
BackgroundOxidative stress, insulin signaling, and diabetes
Rains, J. L., & Jain, S. K. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.12.006 · Cited by 1,435 · cited 1×
“Under conditions of insulin resistance, increased derivatives of oxidative reactions are observed in blood plasma [23,94,95], in adipose and brain tissue, muscle and liver [22,23,96,97].”
BackgroundFarris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E. A., Frosch, M. P., Eckman, C. B., Tanzi, R. E., Selkoe, D. J., & Guénette, S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0230450100 · Cited by 1,286 · cited 1×
“In addition, a decrease in β-amyloid clearance was observed in high-dose insulin mice [58], whereas in mice with absence of both alleles of the insulin degradation enzyme gene, a significant reduction of up to 50% was found in the degradation of βamyloid, resulting in its abnormal concentration in the brain [59].”
BackgroundChronic stress and age-related increases in the proinflammatory cytokine IL-6.
Kiecolt-Glaser, J. K., Preacher, K. J., MacCallum, R. C., Atkinson, C., Malarkey, W. B., & Glaser, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1531903100 · Cited by 1,267 · cited 1×
“Research on chronic stress suggests that interleukin-6 is involved in the progression of AD as well as in the pathology of T2DM [87].”
BackgroundDiabetes mellitus and risk of Alzheimer disease and decline in cognitive function
Arvanitakis, Z., Wilson, R. S., Bienias, J. L., Evans, D. A., & Bennett, D. A. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.661 · Cited by 1,258 · cited 1×
“Insulin resistance affects the way insulin works in target tissues and cells, leading to the well-known phenomenon of hyperglycemia, a condition in which too much glucose circulates in the blood plasma and characterizes T2DM [9] T2DM has also been associated with an increased risk of dementia [10,11] and of AD by 45–9…”
Background13 reasons why the brain is susceptible to oxidative stress
Cobley, J. N., Fiorello, M. L., & Bailey, D. M. (2018) · Redox Biology · doi:10.1016/j.redox.2018.01.008 · Cited by 1,215 · cited 2×
“The human brain is particularly vulnerable to oxidative stress damage [98,99] because although it constitutes a small fraction (less than 2%) of total body weight, it consumes more than 20% of oxygen of the organism.”
BackgroundAlzheimer disease: Epidemiology, diagnostic criteria, risk factors and biomarkers
Reitz, C., & Mayeux, R. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.024 · Cited by 1,181
Alzheimer’s disease is type 3 diabetes—Evidence reviewed
de la Monte, S. M., & Wands, J. R. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200619 · Cited by 1,158
Role of advanced glycation end products in cellular signaling
Ott, C., Jacobs, K., Haucke, E., Navarrete Santos, A., Grune, T., & Simm, A. (2014) · Redox Biology · doi:10.1016/j.redox.2013.12.016 · Cited by 1,150 · cited 2×
“In conclusion, AGEs are a very important link between insulin resistance and neurodegeneration, especially in cases of hyperglycemia [23,112,113].”
BackgroundHypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus
Whitmer, R. A. (2009) · JAMA · doi:10.1001/jama.2009.460 · Cited by 1,128 · cited 3×
“[24] Hypoglycemia In older patients with T2DM, history of severe hypoglycemic episodes was associated with a greater risk of dementia.”
BackgroundIslet Amyloid Polypeptide, Islet Amyloid, and Diabetes Mellitus
Westermark, P., Andersson, A., & Westermark, G. T. (2011) · Physiological Reviews · doi:10.1152/physrev.00042.2009 · Cited by 1,044 · cited 1×
“Like insulin, amylin levels are higher than normal in patients with obesity or insulin resistance, while the coexistence of hyperinsulinemia and hyperamylinemia is common [131,132].”
BackgroundCutler, R. G., Kelly, J., Storie, K., Pedersen, W. A., Tammara, A., Hatanpaa, K., Troncoso, J. C., & Mattson, M. P. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0305799101 · Cited by 1,008 · cited 1×
“In conclusion, AGEs are a very important link between insulin resistance and neurodegeneration, especially in cases of hyperglycemia [23,112,113].”
BackgroundSelective neuronal vulnerability to oxidative stress in the brain
Wang (2010) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2010.00012 · Cited by 1,008
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia
Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., Saunders, A. M., & Hardy, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2635903100 · Cited by 977 · cited 2×
“It has been argued that reduced cerebral glucose metabolism begins in the early stages of AD [88] and that glial cells detect this glucose deficiency [89].”
BackgroundResultIncreased Risk of Type 2 Diabetes in Alzheimer Disease
Janson, J., Laedtke, T., Parisi, J. E., O’Brien, P., Petersen, R. C., & Butler, P. C. (2004) · Diabetes · doi:10.2337/diabetes.53.2.474 · Cited by 950 · cited 2×
“[21] Amyloid deposition in islet and brain cells Higher levels of islet amyloid in AD patients than in control subjects.”
BackgroundMorris, M., Maeda, S., Vossel, K., & Mucke, L. (2011) · Neuron · doi:10.1016/j.neuron.2011.04.009 · Cited by 899
The Amyloid Beta Peptide: A Chemist’s Perspective. Role in Alzheimer’s and Fibrillization
Hamley, I. W. (2012) · Chemical Reviews · doi:10.1021/cr3000994 · Cited by 882 · cited 1×
“The aggregation of the amyloid peptide into oligomers or fibrils, in turn, is involved in the progression of AD [48].”
BackgroundThe many faces of insulin-like peptide signalling in the brain
Fernandez, A. M., & Torres-Alemán, I. (2012) · Nature reviews. Neuroscience · doi:10.1038/nrn3209 · Cited by 872 · cited 1×
“Insulin and IGF-1 play an important role in cognitive ability, neuronal function and development [145], as well as an important role in AD [146].”
BackgroundDiscrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET
Herholz, K., Salmon, E., Perani, D., Baron, J.-C., Holthoff, V., Frölich, L., Schönknecht, P., Ito, K., Mielke, R., & Kalbe, E. (2002) · NeuroImage · doi:10.1006/nimg.2002.1208 · Cited by 832 · cited 2×
“There is evidence that brain metabolism is a key feature of AD [122,123], as well as that the brain’s ability to use glucose to function properly in patients with AD is reduced by up to 25%, mainly in parts of the brain such as the hippocampus [122].”
BackgroundResultInsulin-degrading Enzyme Regulates Extracellular Levels of Amyloid β-Protein by Degradation
Qiu, W. Q., Walsh, D. M., Ye, Z., Vekrellis, K., Zhang, J., Podlisny, M. B., Rosner, M. R., Safavi, A., Hersh, L. B., & Selkoe, D. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.49.32730 · Cited by 812 · cited 1×
“For example, Qiu and colleagues located the IDE in extracellular domains via antibodies and verified that in insulin resistance states where insulin levels are high, the IDE is diverted to insulin degradation, thereby reducing β-amyloid degradation and its toxic accumulation [56].”
BackgroundOxidative Alterations in Alzheimer's Disease
Markesbery, W. R., & Carney, J. M. (1999) · Brain Pathology · doi:10.1111/j.1750-3639.1999.tb00215.x · Cited by 784 · cited 2×
“Active forms of oxygen produced by oxidative stress and the resulting damage are most pronounced in AD in the form of attenuation of ATP (adenosine triphosphate) production, neuronal degeneration and the presence of oxidative stress products in neurofibrillary tangles [79].”
BackgroundThe role of inflammation in Alzheimer’s disease
Tuppo, E. E., & Arias, H. R. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.07.009 · Cited by 734 · cited 3×
“Due to this inflammatory process and the presence of increased levels of inflammatory cytokines, the pathology of AD occurs [78].”
BackgroundDiabetes mellitus and risk of dementia: A meta‐analysis of prospective observational studies
Gudala, K., Bansal, D., Schifano, F., & Bhansali, A. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12087 · Cited by 727 · cited 1×
“What has also been suggested is the coexistence of AGEs and APOE4 gene in the amyloid plaques of patients with dementia and specifically AD [111].”
BackgroundRivera, E. J., Goldin, A., Fulmer, N., Tavares, R., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer s Disease · doi:10.3233/jad-2005-8304 · Cited by 723 · cited 2×
“These metabolic disorders, which accompany AD even from its early stages [26,127], lead to exacerbations of insulin signaling disorders, glucose use and insulin resistance problems [20,34,128], such as decreased acetylcholine (ACh) levels [20], with further aggravation of the pathological condition for those carrying…”
BackgroundHistory and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723 · cited 1×
“Alzheimer’s disease (AD) is a chronic neurodegenerative disease that is the most common type of dementia and is characterized by impaired memory and cognitive ability, as well as changes in behavior and personality [1].”
BackgroundBaker, L. D., Cross, D. J., Minoshima, S., Belongia, D., Watson, G. S., & Craft, S. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.225 · Cited by 639 · cited 1×
“In fact, insulin resistance has been highly correlated with the reduced rate of glucose metabolism in specific areas of the brain such as the frontal, temporal and parietal cortex areas in patients with T2DM [119,120].”
BackgroundRole for neuronal insulin resistance in neurodegenerative diseases
Schubert, M., Gautam, D., Surjo, D., Ueki, K., Baudler, S., Schubert, D., Kondo, T., Alber, J., Galldiks, N., Küstermann, E., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308724101 · Cited by 637 · cited 1×
“Insulin and IGF signaling impairment may result in decreased tau protein expression and hyperphosphorylation due to overactivity by certain kinases and phosphatases [70–72], with GSK-3β (glycogen synthase kinase 3) being the most important.”
BackgroundInsulin Action in Brain Regulates Systemic Metabolism and Brain Function
Kleinridders, A., Ferris, H. A., Cai, W., & Kahn, C. R. (2014) · Diabetes · doi:10.2337/db14-0568 · Cited by 625
Is Alzheimer’s disease a type 3 diabetes? A critical appraisal
Kandimalla, R., Thirumala, V., & Reddy, P. H. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.08.018 · Cited by 621 · cited 1×
“In recent years, with the accumulation of findings suggesting that AD may represent a brain-specific form of DM (type 3 diabetes) [15–17], there has been a growing interest in the role of β-amyloid and tau protein in the peripheral nervous system and its organs, as well as in inducing insulin…”
BackgroundBrain fuel metabolism, aging, and Alzheimer’s disease
Cunnane, S., Nugent, S., Roy, M., Courchesne-Loyer, A., Croteau, E., Tremblay, S., Castellano, A., Pifferi, F., Bocti, C., Paquet, N., et al. (2011) · Nutrition · doi:10.1016/j.nut.2010.07.021 · Cited by 614 · cited 1×
“There is evidence that brain metabolism is a key feature of AD [122,123], as well as that the brain’s ability to use glucose to function properly in patients with AD is reduced by up to 25%, mainly in parts of the brain such as the hippocampus [122].”
BackgroundInvolvement of oxidative stress in Alzheimer disease
Nunomura, A., Castellani, R. J., Zhu, X., Moreira, P. I., Perry, G., & Smith, M. A. (2006) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/01.jnen.0000228136.58062.bf · Cited by 611 · cited 1×
“Thus, while some have argued that β-amyloid precedes oxidative stress [100], many studies suggest that oxidative stress may be a precursor to β-amyloid and tau protein concentration [101,102].”
BackgroundOxidative stress and the etiology of insulin resistance and type 2 diabetes
Henriksen, E. J., Diamond-Stanic, M. K., & Marchionne, E. M. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.12.005 · Cited by 600 · cited 1×
“Under conditions of insulin resistance, increased derivatives of oxidative reactions are observed in blood plasma [23,94,95], in adipose and brain tissue, muscle and liver [22,23,96,97].”
BackgroundInsulin in the brain: There and back again
Banks, W. A., Owen, J. B., & Erickson, M. A. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.006 · Cited by 574 · cited 3×
“Insulin performs many important functions in the brain related to the regulation of food intake, body weight, eating habits and homeostasis of energy [30,31].”
BackgroundInfluentialBhat, R., Xue, Y., Berg, S., Hellberg, S., Ormö, M., Nilsson, Y., Radesäter, A.-C., Jerning, E., Markgren, P.-O., Borgegård, T., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306268200 · Cited by 552 · cited 1×
“Insulin and IGF signaling impairment may result in decreased tau protein expression and hyperphosphorylation due to overactivity by certain kinases and phosphatases [70–72], with GSK-3β (glycogen synthase kinase 3) being the most important.”
BackgroundInsulin and Insulin-like Growth Factor-1 Regulate Tau Phosphorylation in Cultured Human Neurons
Hong, M., & Lee, V. M.-Y. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.31.19547 · Cited by 522 · cited 1×
“GSK-3β has been shown to lead to tau protein phosphorylation; it has also been shown that insulin secretion and action reduce GSK-3β activity by activating the PI3 kinase signaling pathway [73].”
BackgroundBrain Atrophy in Type 2 Diabetes
Moran, C., Phan, T. G., Chen, J., Blizzard, L., Beare, R., Venn, A., Münch, G., Wood, A. G., Forbes, J., Greenaway, T. M., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0143 · Cited by 517 · cited 2×
“[25] T2DM and brain atrophy T2DM is associated with reduced volume of the hippocampus.”
BackgroundEvidence for brain glucose dysregulation in Alzheimer's disease
An, Y., Varma, V. R., Varma, S., Casanova, R., Dammer, E., Pletnikova, O., Chia, C. W., Egan, J. M., Ferrucci, L., Troncoso, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.09.011 · Cited by 507 · cited 3×
“[26] demonstrated that high levels of glucose”
BackgroundBlázquez, E., Velázquez, E., Hurtado-Carneiro, V., & Ruiz-Albusac, J. M. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00161 · Cited by 491 · cited 1×
“Previously, the main source of insulin in the brain was believed to be of peripheral origin, although today various hypotheses are made as to whether the brain produces its own insulin [32–34].”
BackgroundSimpson, I. A., Chundu, K. R., Davies‐Hill, T., Honer, W. G., & Davies, P. (1994) · Annals of Neurology · doi:10.1002/ana.410350507 · Cited by 490 · cited 1×
“Autopsy studies comparing patients with AD and the control group showed reduced levels of glucose transporters (GLUT) in the hippocampus, frontal cortex, parietal lobe and temporal lobe, in patients with AD [125,126].”
BackgroundInsulin resistance in brain alters dopamine turnover and causes behavioral disorders
Kleinridders, A., Cai, W., Cappellucci, L., Ghazarian, A., Collins, W. R., Vienberg, S. G., Pothos, E. N., & Kahn, C. R. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1500877112 · Cited by 486
Brain metabolic dysfunction at the core of Alzheimer's disease
de la Monte, S. M., & Tong, M. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.012 · Cited by 461 · cited 1×
“Insulin and IGF-1 play an important role in cognitive ability, neuronal function and development [145], as well as an important role in AD [146].”
BackgroundImpact of Metabolic Syndrome on Cognition and Brain: A Selected Review of the Literature
Yates, K. F., Sweat, V., Yau, P. L., Turchiano, M. M., & Convit, A. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.252759 · Cited by 444 · cited 1×
“Research over the past decade has linked all the key features of metabolic syndrome, such as visceral obesity [114], various metabolic problems [115,116] and insulin resistance [117] with cognitive impairment and cerebral atrophy [25,118].”
BackgroundPrion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β
Nussbaum, J. M., Schilling, S., Cynis, H., Silva, A., Swanson, E., Wangsanut, T., Tayler, K., Wiltgen, B., Hatami, A., Rönicke, R., et al. (2012) · Nature · doi:10.1038/nature11060 · Cited by 427
Seeding Specificity in Amyloid Growth Induced by Heterologous Fibrils
O'Nuallain, B., Williams, A. D., Westermark, P., & Wetzel, R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311300200 · Cited by 423 · cited 1×
“…the understanding of pathological feedback between AD and T2DM is enhanced by elucidating the molecular relationships between amylin and β-amyloid, as it appears that amylin found in the brains of patients with AD [134,136] may cause amyloid formation [134–142] through heterologous interaction.”
BackgroundAmylin: Pharmacology, Physiology, and Clinical Potential
Hay, D. L., Chen, S., Lutz, T. A., Parkes, D. G., & Roth, J. D. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010629 · Cited by 400 · cited 1×
“Islet amyloid polypeptide (IAPP), otherwise known as amylin, is a hormone that is secreted along with insulin by the β-cells of the pancreatic islets [129] and helps induce satiety in order to regulate blood sugar, inhibit glucagon secretion and delay gastric emptying [130].”
BackgroundInsulin resistance and Alzheimer's disease
De La Monte, S. M. (2009) · BMB Reports · doi:10.5483/bmbrep.2009.42.8.475 · Cited by 392 · cited 3×
“Peripheral insulin resistance induced by T2DM and obesity results in the production of high levels of cytotoxic lipids, which in turn cross the blood-brain barrier and cause neuroinflammation and insulin resistance in the brain [85].”
BackgroundGrünblatt, E., Salkovic‐Petrisic, M., Osmanovic, J., Riederer, P., & Hoyer, S. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04368.x · Cited by 374 · cited 1×
“It has been proposed that oxidative stress and insulin resistance can lead independently to the accumulation of β-amyloid and tau protein [103,104], thus implying a strong correlation with AD pathology.”
BackgroundBlasko, I., Stampfer‐Kountchev, M., Robatscher, P., Veerhuis, R., Eikelenboom, P., & Grubeck‐Loebenstein, B. (2004) · Aging Cell · doi:10.1111/j.1474-9728.2004.00101.x · Cited by 374 · cited 1×
“Moreover, these factors of insulin dysfunction and inflammation, in combination with oxidative stress, enhance the toxicity and concentration of β-amyloid [51] in a pathological feedback cycle.”
BackgroundTau and neuroinflammation: what impact for Alzheimer's disease and tauopathies?
Laurent, C., Buée, L., & Blum, D. (2018) · Biomedical Journal · doi:10.1016/j.bj.2018.01.003 · Cited by 348 · cited 1×
“It has been shown that neuroinflammation contributes to the pathology of AD through oxidative damage [79], tau protein hyperphosphorylation [80], β-amyloid accumulation [78] and by causing cholinergic system dysfunction [81].”
BackgroundAmylin deposition in the brain: A second amyloid in Alzheimer disease?
Jackson, K., Barisone, G. A., Diaz, E., Jin, L., DeCarli, C., & Despa, F. (2013) · Annals of Neurology · doi:10.1002/ana.23956 · Cited by 340 · cited 3×
“…the understanding of pathological feedback between AD and T2DM is enhanced by elucidating the molecular relationships between amylin and β-amyloid, as it appears that amylin found in the brains of patients with AD [134,136] may cause amyloid formation [134–142] through heterologous interaction.”
BackgroundInsulin gene expression and insulin synthesis in mammalian neuronal cells.
Devaskar, S. U., Giddings, S. J., Rajakumar, P. A., Carnaghi, L. R., Menon, R. K., & Zahm, D. S. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37214-9 · Cited by 332
Cook, D. G., Leverenz, J. B., McMillan, P. J., Kulstad, J. J., Ericksen, S., Roth, R. A., Schellenberg, G. D., Jin, L.-W., Kovacina, K. S., & Craft, S. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63822-9 · Cited by 331 · cited 1×
“The expression and activity of this enzyme appears to be reduced in studies with patients who have been diagnosed with genetically inherited forms of AD [61,62].”
BackgroundInsulin and the Blood-Brain Barrier
Woods, S., Seeley, R., Baskin, D., & Schwartz, M. (2003) · Current Pharmaceutical Design · doi:10.2174/1381612033455323 · Cited by 320 · cited 1×
“In contrast to studies that detected insulin mRNA expression, others did not find corresponding mRNA expression in significant amounts to confirm insulin production in the brain [38–41].”
ResultLundmark, K., Westermark, G. T., Olsén, A., & Westermark, P. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501814102 · Cited by 304
Yamagishi, S.-I. (2011) · Experimental Gerontology · doi:10.1016/j.exger.2010.11.007 · Cited by 302 · cited 1×
“AGEs accumulate in various cells as products of the normal course of aging, but their rate of accumulation is increased in patients with DM [106,107].”
BackgroundBosco, D., Fava, A., Plastino, M., Montalcini, T., & Pujia, A. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01318.x · Cited by 283 · cited 3×
“Neuroinflammation is considered by a large number of studies as one of the main causes of insulin and IGF-1 resistance observed in the brain of AD patients [49,84].”
BackgroundIn Vivo Seeding and Cross-Seeding of Localized Amyloidosis
Oskarsson, M. E., Paulsson, J. F., Schultz, S. W., Ingelsson, M., Westermark, P., & Westermark, G. T. (2015) · The American Journal of Pathology · doi:10.1016/j.ajpath.2014.11.016 · Cited by 281 · cited 1×
“Amylin receptors [132–134], as well as amylin deposition [134,135] in the brains of AD patients are observed using immunofluorescence.”
BackgroundPP2A mRNA Expression Is Quantitatively Decreased in Alzheimer's Disease Hippocampus
Vogelsberg-Ragaglia, V., Schuck, T., Trojanowski, J. Q., & Lee, V. M.-Y. (2001) · Experimental Neurology · doi:10.1006/exnr.2001.7630 · Cited by 281 · cited 1×
“According to human and animal studies, the phosphatase PP2A is involved in both AD and T2DM, and its expression is suppressed by insulin administration [74,75].”
BackgroundInsulin in the Cerebrospinal Fluid
MARGOLIS, R. U., & ALTSZULER, N. (1967) · Nature · doi:10.1038/2151375a0 · Cited by 278 · cited 1×
“The increase in insulin concentration in the cerebrospinal fluid (CSF) was first experimentally confirmed by Margolis and Altszuler [28] in mice.”
ResultNeurobiology of Alzheimer′s disease
Mohandas, E., Rajmohan, V, & Raghunath, B. (2009) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.44908 · Cited by 268
Insulin increases CSF Aβ42 levels in normal older adults
Watson, G. S., Peskind, E. R., Asthana, S., Purganan, K., Wait, C., Chapman, D., Schwartz, M. W., Plymate, S., & Craft, S. (2003) · Neurology · doi:10.1212/01.wnl.0000065916.25128.25 · Cited by 264 · cited 1×
“Insulin stimulation plays a key role in the clearance of β-amyloid by preventing extra-cellular accumulation and the final formation of fibrils and plaques [54].”
BackgroundNeuroinflammation – An Early Event in Both the History and Pathogenesis of Alzheimer’s Disease
Eikelenboom, P., van Exel, E., Hoozemans, J. J. M., Veerhuis, R., Rozemuller, A. J. M., & van Gool, W. A. (2010) · Neurodegenerative Diseases · doi:10.1159/000283480 · Cited by 259 · cited 2×
“Although neuroinflammation is an integral part of AD pathophysiology [49,76,77,85], its role in inducing brain insulin resistance and in mediating pathology in T2DM and AD have not been fully established.”
BackgroundAmyloid-β Receptors: The Good, the Bad, and the Prion Protein
Jarosz-Griffiths, H. H., Noble, E., Rushworth, J. V., & Hooper, N. M. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.702704 · Cited by 256 · cited 1×
“In recent years, with the accumulation of findings suggesting that AD may represent a brain-specific form of DM (type 3 diabetes) [15–17], there has been a growing interest in the role of β-amyloid and tau protein in the peripheral nervous system and its organs, as well as in inducing insulin resistance [18,19].”
BackgroundVisceral fat is associated with lower brain volume in healthy middle‐aged adults
Debette, S., Beiser, A., Hoffmann, U., DeCarli, C., O'Donnell, C. J., Massaro, J. M., Au, R., Himali, J. J., Wolf, P. A., Fox, C. S., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22062 · Cited by 253 · cited 1×
“Research over the past decade has linked all the key features of metabolic syndrome, such as visceral obesity [114], various metabolic problems [115,116] and insulin resistance [117] with cognitive impairment and cerebral atrophy [25,118].”
BackgroundStructural Basis for Increased Toxicity of Pathological Aβ42:Aβ40 Ratios in Alzheimer Disease
Pauwels, K., Williams, T. L., Morris, K. L., Jonckheere, W., Vandersteen, A., Kelly, G., Schymkowitz, J., Rousseau, F., Pastore, A., Serpell, L. C., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.264473 · Cited by 253 · cited 1×
“Oligomers are toxic to nerve cells, while mis-folded oligomers can transmit the wrong folding to their neighbors acting as prions [44– 47].”
BackgroundTumminia, A., Vinciguerra, F., Parisi, M., & Frittitta, L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113306 · Cited by 249 · cited 1×
“Hence, the dysregulation of insulin signaling can affect the metabolism and function of APP, eventually leading to the accumulation of Aβ in the cell, which is a major cause for neurodegeneration in AD [52].”
BackgroundExalto, L. G., Biessels, G. J., Karter, A. J., Huang, E. S., Katon, W. J., Minkoff, J. R., & Whitmer, R. A. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70048-2 · Cited by 244 · cited 1×
“Insulin resistance affects the way insulin works in target tissues and cells, leading to the well-known phenomenon of hyperglycemia, a condition in which too much glucose circulates in the blood plasma and characterizes T2DM [9] T2DM has also been associated with an increased risk of dementia [10,11] and of AD by 45–9…”
BackgroundBeta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes
Miklossy, J., Qing, H., Radenovic, A., Kis, A., Vileno, B., Làszló, F., Miller, L., Martins, R. N., Waeber, G., Mooser, V., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.08.019 · Cited by 235 · cited 4×
“Tau protein plays an important role in the peripheral nervous system [19,42,68] as well as in inducing insulin resistance and T2DM [42].”
BackgroundInfluentialCha, M.-Y., Han, S.-H., Son, S. M., Hong, H.-S., Choi, Y.-J., Byun, J., & Mook-Jung, I. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034929 · Cited by 231 · cited 2×
“Thus, while some have argued that β-amyloid precedes oxidative stress [100], many studies suggest that oxidative stress may be a precursor to β-amyloid and tau protein concentration [101,102].”
BackgroundInsulin and insulin-like growth factor receptors in the nervous system
Adamo, M., Raizada, M. K., & LeRoith, D. (1989) · Molecular Neurobiology · doi:10.1007/bf02935589 · Cited by 211 · cited 1×
“In contrast to studies that detected insulin mRNA expression, others did not find corresponding mRNA expression in significant amounts to confirm insulin production in the brain [38–41].”
ResultInsulin Regulates Brain Function, but How Does It Get There?
Gray, S. M., Meijer, R. I., & Barrett, E. J. (2014) · Diabetes · doi:10.2337/db14-0340 · Cited by 206
Andreetto, E., Yan, L., Tatarek‐Nossol, M., Velkova, A., Frank, R., & Kapurniotu, A. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200904902 · Cited by 202 · cited 1×
“Some studies indicate a significant involvement of amylin in the additional amyloid formation in the central nervous system, especially under conditions of hyperamylinemia [137].”
BackgroundBharadwaj, P., Wijesekara, N., Liyanapathirana, M., Newsholme, P., Ittner, L., Fraser, P., & Verdile, G. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-161192 · Cited by 202 · cited 2×
“Tau protein plays an important role in the peripheral nervous system [19,42,68] as well as in inducing insulin resistance and T2DM [42].”
BackgroundMehlhorn, G., Hollborn, M., & Schliebs, R. (2000) · International Journal of Developmental Neuroscience · doi:10.1016/s0736-5748(00)00012-5 · Cited by 198 · cited 1×
“The presence of high levels of inflammatory cytokines, such as interleukin-1β (IL-1β), IL-6 and interferon-gamma in close proximity to β-amyloid plaques and macrophage cells supports the important role of neuroinflammation in the pathology of AD [82,83].”
BackgroundDifferential expression of the two nonallelic proinsulin genes in the developing mouse embryo.
Deltour, L., Leduque, P., Blume, N., Madsen, O., Dubois, P., Jami, J., & Bucchini, D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.527 · Cited by 193 · cited 1×
“Insulin mRNA expression has been found in specific areas of the brain in mice, and insulin peptide production has also been observed in cultured neurons but not in glial cells from mice brains [35–37].”
Backgroundde la Monte, S. M., Longato, L., Tong, M., & Wands, J. R. (2009) · PubMed · Cited by 190
Giovannini, M. G., Scali, C., Prosperi, C., Bellucci, A., Vannucchi, M. G., Rosi, S., Pepeu, G., & Casamenti, F. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2002.0538 · Cited by 190 · cited 1×
“It has been shown that neuroinflammation contributes to the pathology of AD through oxidative damage [79], tau protein hyperphosphorylation [80], β-amyloid accumulation [78] and by causing cholinergic system dysfunction [81].”
BackgroundSripetchwandee, J., Chattipakorn, N., & Chattipakorn, S. C. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00496 · Cited by 190 · cited 1×
“Under conditions of insulin resistance, increased derivatives of oxidative reactions are observed in blood plasma [23,94,95], in adipose and brain tissue, muscle and liver [22,23,96,97].”
BackgroundClodfelder-Miller, B. J., Zmijewska, A. A., Johnson, G. V. W., & Jope, R. S. (2006) · Diabetes · doi:10.2337/db06-0485 · Cited by 185 · cited 1×
“According to human and animal studies, the phosphatase PP2A is involved in both AD and T2DM, and its expression is suppressed by insulin administration [74,75].”
BackgroundInsulin-Degrading Enzyme in the Fight against Alzheimer's Disease
Kurochkin, I. V., Guarnera, E., & Berezovsky, I. N. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.10.008 · Cited by 185 · cited 1×
“Insulindegrading enzyme (IDE) is the major degradation peptidase of β-amyloid, and due to its ability to degrade insulin, amylin and β-amyloid, it is thought to play a linking role between insulin resistance and AD [55].”
BackgroundNeuroinflammatory perspectives on the two faces of Alzheimer?s disease
Eikelenboom, P., & van Gool, W. A. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-003-0055-1 · Cited by 182
Roberts, R. O., Knopman, D. S., Cha, R. H., Mielke, M. M., Pankratz, V. S., Boeve, B. F., Kantarci, K., Geda, Y. E., Jack, C. R., Petersen, R. C., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.132647 · Cited by 162 · cited 1×
“In fact, insulin resistance has been highly correlated with the reduced rate of glucose metabolism in specific areas of the brain such as the frontal, temporal and parietal cortex areas in patients with T2DM [119,120].”
BackgroundClinical aspects of inflammation in Alzheimer's disease
Rosenberg, P. B. (2005) · International Review of Psychiatry · doi:10.1080/02646830500382037 · Cited by 158 · cited 2×
“One of the most important processes involved in neuroinflammation is the beta-amyloid-induced activation of microglial cells [86], which in turn leads to the release of various inflammatory cytokines such as interleukin-6 and tumor necrosis factor alpha (TNF-a).”
BackgroundHoyer, S., & Nitsch, R. M. (1989) · Journal of Neural Transmission · doi:10.1007/bf01258634 · Cited by 153 · cited 1×
“Insulin resistance in the brain as a feature of AD was first proposed in an earlier study by Hoyer and Nitsch (1989) to explain the metabolic disorders of the brain and more specifically as the main explanation for the low glucose metabolism observed during the AD [147].”
BackgroundRisk of Alzheimer’s Disease in Relation to Diabetes: A Population-Based Cohort Study
Wang, K.-C., Woung, L.-C., Tsai, M.-T., Liu, C.-C., Su, Y.-H., & Li, C.-Y. (2012) · Neuroepidemiology · doi:10.1159/000337428 · Cited by 148 · cited 1×
“…well-known phenomenon of hyperglycemia, a condition in which too much glucose circulates in the blood plasma and characterizes T2DM [9] T2DM has also been associated with an increased risk of dementia [10,11] and of AD by 45-90% [12,13] as well as an increased risk of AD in patients with T2DM [14].”
BackgroundInsulin II gene expression in rat central nervous system
Devaskar, S. U., Singh, B. S., Carnaghi, L. R., Rajakumar, P. A., & Giddings, S. J. (1993) · Regulatory Peptides · doi:10.1016/0167-0115(93)90335-6 · Cited by 137
Tan, Z. S., Beiser, A. S., Fox, C. S., Au, R., Himali, J. J., Debette, S., DeCarli, C., Vasan, R. S., Wolf, P. A., & Seshadri, S. (2011) · Diabetes Care · doi:10.2337/dc11-0308 · Cited by 135 · cited 1×
“Research over the past decade has linked all the key features of metabolic syndrome, such as visceral obesity [114], various metabolic problems [115,116] and insulin resistance [117] with cognitive impairment and cerebral atrophy [25,118].”
BackgroundToxic Advanced Glycation End Products (TAGE) Theory in Alzheimer’s Disease
Sato, T., Shimogaito, N., Wu, X., Kikuchi, S., Yamagishi, S.-I., & Takeuchi, M. (2006) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317506289277 · Cited by 132 · cited 3×
“AGEs interact with their receptors (RAGE) and activate several signaling mechanisms that cause increased oxidative stress and organ damage, leading to complications [108].”
BackgroundInfluentialInsulin dysfunction and Tau pathology
El Khoury, N. B., Gratuze, M., Papon, M.-A., Bretteville, A., & Planel, E. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00022 · Cited by 130 · cited 1×
“In its normal state, tau protein is responsible for microtubule stability and regulating intracellular signaling [63–66].”
BackgroundMaciejczyk, M., Żebrowska, E., Zalewska, A., & Chabowski, A. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/6940515 · Cited by 125 · cited 4×
“In conclusion, AGEs are a very important link between insulin resistance and neurodegeneration, especially in cases of hyperglycemia [23,112,113].”
BackgroundInfluentialKuhla, B., Haase, C., Flach, K., Lüth, H.-J., Arendt, T., & Münch, G. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m609521200 · Cited by 119 · cited 1×
“Furthermore, it also appears that tau protein glycation may promote the formation of paired helical fibers [110].”
BackgroundAlzheimer disease: A tale of two prions
Nussbaum, J. M., Seward, M. E., & Bloom, G. S. (2013) · Prion · doi:10.4161/pri.22118 · Cited by 117
Chen, G.-J., Xu, J., Lahousse, S. A., Caggiano, N. L., & de la Monte, S. M. (2003) · Journal of Alzheimer's Disease · doi:10.3233/jad-2003-5305 · Cited by 115 · cited 1×
“It has been proposed that oxidative stress and insulin resistance can lead independently to the accumulation of β-amyloid and tau protein [103,104], thus implying a strong correlation with AD pathology.”
BackgroundType 2 diabetes mellitus is associated with brain atrophy and hypometabolism in the ADNI cohort
Li, W., Risacher, S. L., Huang, E., Saykin, A. J., & Initiative, F. T. A. D. N. (2016) · Neurology · doi:10.1212/wnl.0000000000002950 · Cited by 114 · cited 1×
“In addition, in the white and gray matter of patients with T2DM who also suffer from mild cognitive impairment (MCI), a total cerebral decrease in FDG (18-fluoro-deoxyglucose) intake has been observed [121].”
BackgroundAPOE2 eases cognitive decline during Aging: Clinical and preclinical evaluations
Shinohara, M., Kanekiyo, T., Yang, L., Linthicum, D., Shinohara, M., Fu, Y., Price, L., Frisch‐Daiello, J. L., Han, X., Fryer, J. D., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24628 · Cited by 111
Glucose Peaks and the Risk of Dementia and 20-Year Cognitive Decline
Rawlings, A. M., Sharrett, A. R., Mosley, T. H., Ballew, S. H., Deal, J. A., & Selvin, E. (2017) · Diabetes Care · doi:10.2337/dc16-2203 · Cited by 111 · cited 1×
“Based on existing evidence, we now know that insulin resistance, hypoglycemia [24] and hyperglycemia are associated with cognitive decline [144] and are key features of T2DM.”
BackgroundApoprotein E and Reverse Cholesterol Transport
Getz, G. S., & Reardon, C. A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113479 · Cited by 111 · cited 1×
“APOE is a lipid-binding protein with a key role in cholesterol homeostasis [7].”
BackgroundLacovich, V., Espindola, S. L., Alloatti, M., Pozo Devoto, V., Cromberg, L. E., Čarná, M. E., Forte, G., Gallo, J.-M., Bruno, L., Stokin, G. B., et al. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.2305-16.2016 · Cited by 107
Miller, Y., Ma, B., & Nussinov, R. (2011) · Biochemistry · doi:10.1021/bi200400u · Cited by 106 · cited 1×
“Oligomers are toxic to nerve cells, while mis-folded oligomers can transmit the wrong folding to their neighbors acting as prions [44– 47].”
BackgroundGonçalves, R. A., Wijesekara, N., Fraser, P. E., & De Felice, F. G. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00017 · Cited by 105 · cited 1×
“Tau protein plays an important role in the peripheral nervous system [19,42,68] as well as in inducing insulin resistance and T2DM [42].”
BackgroundAmylin at the interface between metabolic and neurodegenerative disorders
Lutz, T. A., & Meyer, U. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00216 · Cited by 100 · cited 1×
“Like insulin, amylin levels are higher than normal in patients with obesity or insulin resistance, while the coexistence of hyperinsulinemia and hyperamylinemia is common [131,132].”
BackgroundBrain Insulin Impairs Amyloid-β(1-40) Clearance from the Brain
Shiiki, T., Ohtsuki, S., Kurihara, A., Naganuma, H., Nishimura, K., Tachikawa, M., Hosoya, K.-I., & Terasaki, T. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.2236-04.2004 · Cited by 100 · cited 1×
“In addition, a decrease in β-amyloid clearance was observed in high-dose insulin mice [58], whereas in mice with absence of both alleles of the insulin degradation enzyme gene, a significant reduction of up to 50% was found in the degradation of βamyloid, resulting in its abnormal concentration in the brain [59].”
BackgroundLangbaum, J. B. S., Chen, K., Caselli, R. J., Lee, W., Reschke, C., Bandy, D., Alexander, G. E., Burns, C. M., Kaszniak, A. W., Reeder, S. A., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.30 · Cited by 100 · cited 1×
“These metabolic disorders, which accompany AD even from its early stages [26,127], lead to exacerbations of insulin signaling disorders, glucose use and insulin resistance problems [20,34,128], such as decreased acetylcholine (ACh) levels [20], with further aggravation of the pathological condition for those carrying…”
BackgroundThe effect of curcumin on human islet amyloid polypeptide misfolding and toxicity
Daval, M., Bedrood, S., Gurlo, T., Huang, C., Costes, S., Butler, P. C., & Langen, R. (2010) · Amyloid · doi:10.3109/13506129.2010.530008 · Cited by 100 · cited 1×
“Additionally, the presence of tau protein hyperphosphorylation has also been demonstrated in the pancreatic islets of transgenic mice with T2DM and AD [69].”
BackgroundFu, W., Ruangkittisakul, A., MacTavish, D., Shi, J. Y., Ballanyi, K., & Jhamandas, J. H. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.331181 · Cited by 93
Kim, M., Hersh, L. B., Leissring, M. A., Ingelsson, M., Matsui, T., Farris, W., Lu, A., Hyman, B. T., Selkoe, D. J., Bertram, L., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m609168200 · Cited by 93 · cited 1×
“The expression and activity of this enzyme appears to be reduced in studies with patients who have been diagnosed with genetically inherited forms of AD [61,62].”
BackgroundGu, F., Zhu, M., Shi, J., Hu, Y., & Zhao, Z. Y. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.05.050 · Cited by 91 · cited 1×
“Thus, while some have argued that β-amyloid precedes oxidative stress [100], many studies suggest that oxidative stress may be a precursor to β-amyloid and tau protein concentration [101,102].”
BackgroundIslet Amyloid Polypeptide (IAPP): A Second Amyloid in Alzheimer's Disease
Fawver, J., Ghiwot, Y., Koola, C., Carrera, W., Rodriguez-Rivera, J., Hernandez, C., Dineley, K., Kong, Y., Li, J., Jhamandas, J., et al. (2014) · Current Alzheimer Research · doi:10.2174/1567205011666141107124538 · Cited by 90
An Integrated and Unifying Hypothesis for the Metabolic Basis of Sporadic Alzheimer's Disease
Erol, A. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-13302 · Cited by 89 · cited 2×
“This deficiency, supported by systemic hyperinsulinemia, leads to the perpetuation of inflammation through its inhibition of AMPK (5’ AMP-activated protein kinase) [89].”
BackgroundAnalysis of tyrosine hydroxylase and insulin transcripts in human neuroendocrine tissues
Coker, G. T., Studelska, D. R., Harmon, S., Burke, W. J., & O’Malley, K. L. (1990) · Molecular Brain Research · doi:10.1016/0169-328x(90)90052-f · Cited by 85
Is Insulin Resistant Brain State a Central Feature of the Metabolic-Cognitive Syndrome?
Frisardi, V., Solfrizzi, V., Capurso, C., Imbimbo, B. P., Vendemiale, G., Seripa, D., Pilotto, A., & Panza, F. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100015 · Cited by 83 · cited 1×
“Research over the past decade has linked all the key features of metabolic syndrome, such as visceral obesity [114], various metabolic problems [115,116] and insulin resistance [117] with cognitive impairment and cerebral atrophy [25,118].”
BackgroundDevelopmental regulation of insulin in the mammalian central nervous system
Schechter, R., Whitmire, J., Holtzclaw, L. A., George, M., Harlow, R. D., & Devaskar, S. U. (1992) · Brain Research · doi:10.1016/0006-8993(92)90313-x · Cited by 81 · cited 1×
“Insulin mRNA expression has been found in specific areas of the brain in mice, and insulin peptide production has also been observed in cultured neurons but not in glial cells from mice brains [35–37].”
BackgroundStarks, E. J., Patrick O’Grady, J., Hoscheidt, S. M., Racine, A. M., Carlsson, C. M., Zetterberg, H., Blennow, K., Okonkwo, O. C., Puglielli, L., Asthana, S., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150072 · Cited by 78 · cited 1×
“In mice, it has been shown that increased γ-secretase activity due to insulin resistance leads to increased amyloid in the brain, as well as decreased activity of the IDE [57].”
BackgroundSato, N., & Morishita, R. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00143 · Cited by 78 · cited 2×
“It has also been shown that T2DM deregulates mitochondrial function in mice, as well as impairs neurite outgrowth through JAK/STAT3 modulation of mitochondrial bioenergetics [27].”
BackgroundChetram Deochand, M. T. (2013) · Journal of Alzheimer’s Disease & Parkinsonism · doi:10.4172/2161-0460.1000128 · Cited by 76 · cited 1×
“There are indications that insulin resistance in T2DM may be considered as a factor that increases and promotes oxidative stress leading to the neurodegeneration of AD [90].”
BackgroundVerma, N., Ly, H., Liu, M., Chen, J., Zhu, H., Chow, M., Hersh, L. B., & Despa, F. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160047 · Cited by 75 · cited 1×
“Amylin resistance and hyperamylinemia may be targets of the therapeutic approach against AD [143].”
Backgroundde la Monte, S. M., Tong, M., & Wands, J. R. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170829 · Cited by 75
Exogenous amyloidogenic proteins function as seeds in amyloid β-protein aggregation
Ono, K., Takahashi, R., Ikeda, T., Mizuguchi, M., Hamaguchi, T., & Yamada, M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.01.002 · Cited by 74
Insulin is differentially related to cognitive decline and atrophy in Alzheimer's disease and aging
Burns, J. M., Honea, R. A., Vidoni, E. D., Hutfles, L. J., Brooks, W. M., & Swerdlow, R. H. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.06.011 · Cited by 73 · cited 1×
“Research over the past decade has linked all the key features of metabolic syndrome, such as visceral obesity [114], various metabolic problems [115,116] and insulin resistance [117] with cognitive impairment and cerebral atrophy [25,118].”
BackgroundWoltjer, R. L., Maezawa, I., Ou, J. J., Montine, K. S., & Montine, T. J. (2004) · Journal of Alzheimer's Disease · doi:10.3233/jad-2003-5607 · Cited by 68 · cited 1×
“AGEs promote the aggregation of amyloid oligomers, thus contributing to the neurotoxic effects observed in AD [109].”
BackgroundIn Silico Cross Seeding of Aβ and Amylin Fibril-like Oligomers
Berhanu, W. M., Yaşar, F., & Hansmann, U. H. E. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn400141x · Cited by 67
Determination of regional cerebral function with FDG-PET imaging in neuropsychiatric disorders
Newberg, A. B., Alavi, A. A., & Reivich, M. (2002) · Seminars in Nuclear Medicine · doi:10.1053/snuc.2002.29276 · Cited by 67 · cited 1×
“This reduced metabolism of cerebral glucose in patients with AD has been repeatedly confirmed by several research studies [88,123,124].”
ResultThe interaction of amylin with other hormones in the control of eating
Lutz, T. A. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01670.x · Cited by 63 · cited 1×
“Islet amyloid polypeptide (IAPP), otherwise known as amylin, is a hormone that is secreted along with insulin by the β-cells of the pancreatic islets [129] and helps induce satiety in order to regulate blood sugar, inhibit glucagon secretion and delay gastric emptying [130].”
BackgroundD’Andrea, M. R., Reiser, P. A., Gumula, N. A., Hertzog, B. M., & Andrade‐Gordon, P. (2001) · Biotechnic & Histochemistry · doi:10.1080/714028132 · Cited by 60 · cited 1×
“The presence of high levels of inflammatory cytokines, such as interleukin-1β (IL-1β), IL-6 and interferon-gamma in close proximity to β-amyloid plaques and macrophage cells supports the important role of neuroinflammation in the pathology of AD [82,83].”
BackgroundŻukowski, P., Maciejczyk, M., Matczuk, J., Kurek, K., Waszkiel, D., Żendzian-Piotrowska, M., & Zalewska, A. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/6581970 · Cited by 58
de la Monte, S. M., Tong, M., Bowling, N., & Moskal, P. (2011) · Molecular Brain · doi:10.1186/1756-6606-4-13 · Cited by 57
Rorbach-Dolata, A., & Piwowar, A. (2019) · BioMed Research International · doi:10.1155/2019/1435276 · Cited by 57 · cited 3×
“Amylin is incorporated into neurons and acts on them with the same toxicity that is observed in the pancreatic islets in individuals with T2DM, causing intracellular oxidative stress and inflammatory responses [136].”
BackgroundInfluentialOxidative Stress in Diabetes Mellitus: Is There a Role for Hypoglycemic Drugs and/or Antioxidants?
Erejuwa, O. O. (2012) · InTech eBooks · doi:10.5772/32741 · Cited by 54 · cited 1×
“Mitochondrial dysfunction and the overproduction of reactive oxygen species play a vital role in the development of T2DM pathology [93].”
BackgroundInsulin-Degrading Enzyme, Apolipoprotein E, and Alzheimer's Disease
Edland, S. D. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:23:3:213 · Cited by 54 · cited 1×
“In patients with AD who carry the APOE4 gene, the expression of IDE is quite reduced in areas of the brain such as the hippocampus [60].”
BackgroundDiabetes: Risk factor and translational therapeutic implications for Alzheimer's disease
Cummings, J., Ortiz, A., Castellino, J., & Kinney, J. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15619 · Cited by 48 · cited 1×
“The exact cause of AD is not fully understood; there is therefore currently no effective treatment despite the large number of clinical studies that have been performed [4].”
BackgroundKulas, J. A., Franklin, W. F., Smith, N. A., Manocha, G. D., Puig, K. L., Nagamoto-Combs, K., Hendrix, R. D., Taglialatela, G., Barger, S. W., & Combs, C. K. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00279.2018 · Cited by 41 · cited 1×
“Evidence shows that APP is essential for maintaining a healthy glycemic regulation, and it has been observed that APP knockdown mice develop metabolic disorders [53].”
BackgroundKalaria, R. N., & Harik, S. I. (1989) · PubMed · Cited by 33
Cerebrospinal fluid insulin during non-neurological surgery
Bromander, S., Anckarsäter, R., Åhrén, B., Kristiansson, M., Blennow, K., Holmäng, A. B., Zetterberg, H., Anckarsäter, H. S., & Wass, C. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0456-x · Cited by 29 · cited 1×
“The highest percentage of insulin in the brain is derived from pancreatic peripheral neural insulin [29].”
BackgroundInhibiting the formation of classical C3-convertase on the Alzheimer's β-amyloid peptide
Emmerling, M. R., Spiegel, M. K., & Watson, D. (1997) · Immunopharmacology · doi:10.1016/s0162-3109(97)00067-2 · Cited by 28 · cited 1×
“quently, increased β-amyloid levels antagonize insulin and IGF-1 receptor binding, which results in the secretion of inflammatory agents and the onset of insulin resistance [50].”
BackgroundKALARIA, R. N., & HARIK, S. I. (1988) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-198802030-00087 · Cited by 28 · cited 1×
“Autopsy studies comparing patients with AD and the control group showed reduced levels of glucose transporters (GLUT) in the hippocampus, frontal cortex, parietal lobe and temporal lobe, in patients with AD [125,126].”
BackgroundDiabetes and Aging-related Complications
(2017) · Springer eBooks · doi:10.1007/978-981-10-4376-5 · Cited by 11
Cummings, J. L., Ortiz, A., Castellino, J., & Kinney, J. W. (2022) · Publons reviews and discussion · doi:10.1111/ejn.15619/v2/response1 · Cited by 2
Cited by
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., Ames, D., Banerjee, S., Burns, A., Brayne, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01296-0 · Cited by 3,860
Metabolic Syndrome as a Risk Factor for Alzheimer’s Disease: A Focus on Insulin Resistance
Ezkurdia, A., Ramírez, M. J., & Solas, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054354 · Cited by 169
GLP-1 Receptor Agonists: A New Treatment in Parkinson’s Disease
Kalinderi, K., Papaliagkas, V. T., & Fidani, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073812 · Cited by 130
“Recent data highlight similarities between neurodegenerative diseases, including PD and type 2 diabetes mellitus (T2DM) [5], suggesting that the homeostasis in the gut–brain axis is fundamental for the maintenance of health in both central nervous system (CNS) and peripheral system, and these…”
BackgroundSelf-citationKim, O. Y., & Song, J. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122356 · Cited by 102
Giacomo, S. D., Percaccio, E., Gullì, M., Romano, A., Vitalone, A., Mazzanti, G., Gaetani, S., & Sotto, A. D. (2022) · Nutrients · doi:10.3390/nu14183709 · Cited by 93
“Moreover, other contributing factors, including the presence of neurofibrillary tangles containing hyperphosphorylated tau protein within neurons, neuroinflammation, neurotransmitter deficits, and neurodegeneration, which finally lead to neuronal death, have been highlighted [5].”
Background
Metadata
- Authors
- Michailidis, M., Moraitou, D., Tata, D. A., Kalinderi, K., Papamitsou, T., & Papaliagkas, V.
- Affiliations
- Laboratory of Psychology, School of Psychology, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
- Aristotle University of Thessaloniki (GR)
- International Hellenic University (GR)
- Corresponding author
- Papaliagkas, Vasileios
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-02-28
- Volume
- 23
- Issue
- 5
- Pages
- 2687
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8910482
- OpenAlex
- W4214581316
- Cited by
- 330
- References
- 150
- Citations by year
- 2026: 79 · 2025: 110 · 2024: 71 · 2023: 61 · 2022: 9
- FWCI
- 8.63
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
- Keywords
- Alzheimer's disease, type 2 diabetes, type 3 diabetes, insulin resistance, insulin signaling, neuroinflammation, oxidative stress, advanced glycation end products, mitochondrial dysfunction, metabolic syndrome, amyloid-beta, tau protein, amylin, cognitive impairment, brain energy homeostasis
- MeSH terms
- Alzheimer Disease, Brain, Diabetes Mellitus, Type 2, Humans, Insulin, Insulin Resistance, Amyloid beta-Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
